Yasunao Kogashiwa1, Masanori Yasuda2, Hiroyuki Sakurai3, Mitsuhiko Nakahira4, Yoshie Sano4, Kenji Gonda5, Tetsuya Ikeda6, Hitoshi Inoue4, Kiyomi Kuba4, Susumu Oba4, Junichi Ishikawa4, Yuichiro Enoki4, Satoko Matsumura4, Kazuhiko Minami4, Yasuhiro Ebihara4, Masashi Sugasawa4. 1. Department of Head and Neck Surgery, and Otolaryngology, Saitama Medical University International Medical Center, Hidaka, Japan y_koga@saitama-med.ac.jp. 2. Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Japan. 3. Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Mitaka, Japan. 4. Department of Head and Neck Surgery, and Otolaryngology, Saitama Medical University International Medical Center, Hidaka, Japan. 5. Department of Surgery, Japan Community Health Care Organization, Nihonmatsu, Japan. 6. Department of Otolaryngology, Head and Neck Surgery, Kyorin University School of Medicine, Mitaka, Japan.
Abstract
BACKGROUND/AIM: Clinical trials with therapies targeting immune checkpoint molecules have shown promising results in several tumor types. However, the predictive and prognostic values of these immunological factors for locally advanced oral squamous cell carcinomas (LAOSCC) remain unclear. Our purpose was to evaluate the expression and prognostic value of programmed cell death-ligand1 (PD-L1) and PD-L2 and to correlate their expression with the degree of infiltration by CD8+ cells in LAOSCC. PATIENTS AND METHODS: A total of 84 patients with LAOSCC were included. PD-L1, PD-L2 and CD8 expression was detected in the tumor tissue using immunohistochemistry and was tested for correlation with clinical outcome. RESULTS: PD-L1 and PD-L2 were expressed in 52.4% and 23.8% of LAOSCC cases, respectively. PD-L1 positivity was significantly associated with superior disease-free (p=0.024) and overall (p=0.008) survival of the patients and retained significance in multivariate analysis. PD-L1 positivity was correlated with CD8 density. CONCLUSION: PD-L1 expression was associated with CD8+ tumor-infiltrating lymphocytes and better outcome in patients with LAOSCC. Copyright
BACKGROUND/AIM: Clinical trials with therapies targeting immune checkpoint molecules have shown promising results in several tumor types. However, the predictive and prognostic values of these immunological factors for locally advanced oral squamous cell carcinomas (LAOSCC) remain unclear. Our purpose was to evaluate the expression and prognostic value of programmed cell death-ligand1 (PD-L1) and PD-L2 and to correlate their expression with the degree of infiltration by CD8+ cells in LAOSCC. PATIENTS AND METHODS: A total of 84 patients with LAOSCC were included. PD-L1, PD-L2 and CD8 expression was detected in the tumor tissue using immunohistochemistry and was tested for correlation with clinical outcome. RESULTS:PD-L1 and PD-L2 were expressed in 52.4% and 23.8% of LAOSCC cases, respectively. PD-L1 positivity was significantly associated with superior disease-free (p=0.024) and overall (p=0.008) survival of the patients and retained significance in multivariate analysis. PD-L1 positivity was correlated with CD8 density. CONCLUSION:PD-L1 expression was associated with CD8+ tumor-infiltrating lymphocytes and better outcome in patients with LAOSCC. Copyright
Authors: Giuseppe Troiano; Vito C A Caponio; Khrystyna Zhurakivska; Claudia Arena; Giuseppe Pannone; Marco Mascitti; Andrea Santarelli; Lorenzo Lo Muzio Journal: Cell Prolif Date: 2018-11-15 Impact factor: 6.831